Announcements

10 May 2013	Results of Annual General Meeting
24 April 2013	Nutrition Science Partners announces initiation and treatment of the first Ulcerative Colitis patient in the global NATRUL Phase III trial for the novel botanical oral drug HMPL-004
12 April 2013	Nestle Health Science and Chi-Med complete regulatory approvals for the establishment of Nutrition Science Partners Joint Venture
09 April 2013	2012 Annual Report and Notice of Annual General Meeting
08 April 2013	Presentations of Fruquintinib Phase I Clinical Data and Volitinib Preclinical Data at the 2013 AACR Annual Meeting
26 March 2013	Final Results for the year ended 31 December 2012
28 February 2013	Total Voting Rights
18 February 2013	Notice of Announcement of 2012 Final Results
28 January 2013	TR-1: Notification of major interest in shares
31 December 2012	Blocklisting Six Monthly Return
28 November 2012	Chi-Med and Nestlé Health Science establish Joint Venture
01 November 2012	Hutchison MediPharma Limited initiates Phase I clinical study with its novel EGFR inhibitor Theliatinib
08 October 2012	TR-1: Notification of major interest in shares
28 September 2012	Total Voting Rights
13 September 2012	Director's Shareholding
28 August 2012	Change of Nominated Adviser
31 July 2012	Interim Results for the Six Months Ended 30 June 2012
05 July 2012	Total Voting Rights
29 June 2012	Announcement on Blocklisting Six Monthly Return
28 June 2012	Notice of Announcement of 2012 Interim Results
14 June 2012	Exercise of Options
06 June 2012	Hutchison MediPharma Limited Announces Presentations of Sulfatinib and Fruquintinib Clinical Data at the 2012 ASCO Annual Meeting
30 May 2012	Director's Shareholding
11 May 2012	Results of Annual General Meeting
10 April 2012	2011 Annual Report and Notice of Annual General Meeting
20 March 2012	Final Results for the year ended 31 December 2011. Strong growth. Positive outlook
22 February 2012	Hutchison MediPharma Limited initiates Phase I clinical study of its novel c-Met inhibitor Volitinib
20 February 2012	Notice of Announcement of 2011 Final Results
14 February 2012	TR-1: Notification of major interests in shares
02 February 2012	Total Voting Rights
05 January 2012	TR-1: Notification of major interest in shares
29 December 2011	Blocklisting Six Monthly Return
21 December 2011	AstraZeneca and Chi-Med enter into global collaboration to co-develop and commercialise novel cancer therapy
12 December 2011	Chi-Med Loan Facility
04 November 2011	Hutchison MediPharma Limited initiates Phase I clinical study for its novel EGFR inhibitor Epitinib
05 September 2011	TR-1: Notification of major interests in shares
01 August 2011	Interim Results for the Six Months Ended 30 June 2011
22 July 2011	China Healthcare Division expands OTC drug distribution and marketing operations
05 July 2011	Notice of Announcement of 2011 Interim Results
29 June 2011	Blocklisting Six Monthly Return
13 May 2011	TR-1: Notification of major interests in shares
09 May 2011	Results of Annual General Meeting
09 May 2011	TR-1: Notification of major interests in shares
04 April 2011	2010 Annual Report and Notice of Annual General Meeting
28 March 2011	Director's Shareholding
09 March 2011	Final Results for the year ended 31 December 2010 Strong performance across all divisions.
21 February 2011	Board Change
15 February 2011	Appointment of UBS Limited as Joint Broker
01 February 2011	Fruquintinib receives SFDA IND approval Starts Phase I Clinical Trial for the treatment of cancer
31 January 2011	Notice of Announcement of 2010 Final Results
05 January 2011	Total Voting Rights
29 December 2010	Blocklisting Six Monthly Return
21 December 2010	Hutchison MediPharma Receives Further Strategic Investment to Advance Its Pipeline
10 December 2010	China Healthcare Division Chi-Med increases indirect ownership of its Hutchison Baiyunshan joint venture
08 November 2010	Hutchison MediPharma Receives Strategic Investment to Advance Its Pipeline
20 September 2010	Hutchison Hain Organic launch EARTH'S BEST® and ZHI LING TONG Co-branded Infant formula in China
15 September 2010	Appointment of Joint Broker
29 July 2010	Interim Results for the Six Months Ended 30 June 2010 Strong results. Continued momentum. Positive outlook.
14 July 2010	TR-1: Notification of major interests in shares
07 July 2010	TR-1: Notification of major interests in shares
07 July 2010	Notice of Announcement of 2010 Interim Results
05 July 2010	Total Voting Rights
29 June 2010	Blocklisting Six Monthly Return
25 June 2010	Director's Shareholding
17 June 2010	TR-1: Notification of major interests in shares
30 April 2010	Results of Annual General Meeting
30 April 2010	Hutchison MediPharma Limited Receives SFDA IND Approval and Begins Phase I Clinical Trial of Sulfatinib for the Treatment of Cancer
19 April 2010	Seven-year extension of IP protection for Chi-Med's main prescription drug
29 March 2010	2009 Annual Report and Notice of Annual General Meeting
15 March 2010	TR-1: Notification of major interests in shares
12 March 2010	TR-1: Notification of major interests in shares
10 March 2010	TR-1: Notification of major interests in shares
08 March 2010	TR-1: Notification of Major Interests in Shares
04 March 2010	Final Results for the year ended 31 December 2009 Strong results. Momentum continues. Positive outlook.
08 February 2010	Notice of Announcement of 2009 Final Results
02 February 2010	Total Voting Rights
19 January 2010	Three more of Chi-Med's China Healthcare Division drugs added to latest China's National Medicines Catalogue
04 January 2010	Total Voting Rights
29 December 2009	Blocklisting Six Monthly Return
26 November 2009	TR-1 : Notification of Major Interests in Shares
05 November 2009	Successful Global Phase IIb Ulcerative Colitis Trial for HMPL-004: All Primary and Secondary Endpoints Achieved Hutchison MediPharma Proceeding with Development and Partnership Plans
30 October 2009	Hutchison MediPharma Limited Initiates Phase I Clinical Trial of HMPL-011, Its Novel Single Chemical Drug Candidate for the Treatment of Auto-immune Diseases
26 October 2009	Chi-Med increases ownership of its Hutchison Healthcare joint venture to 100%
16 October 2009	Newly Published China National Essential Medicines List Reference Prices No Overall Negative Impact on Chi-Med Prices
08 October 2009	Chi-Med announces joint venture with The Hain Celestial Group to develop natural and organic consumer products in Asia
27 August 2009	Chi-Med's Main Drugs Included in the New National Essential Medicines List
30 July 2009	Interim Results for the Six Months Ended 30 June 2009
29 July 2009	Patient Enrolment Completed Ahead of Schedule for the Global Phase IIb Ulcerative Colitis Trial of HMPL-004
13 July 2009	Phase II Crohn's Disease Trial for HMPL-004 Delivers Encouraging Results
08 July 2009	Notice of Announcement of 2009 Interim Results
30 June 2009	Blocklisting Six Monthly Return
08 May 2009	Results of Annual General Meeting
09 April 2009	Director's Shareholding
06 April 2009	2008 Annual Report and Notice of Annual General Meeting
20 March 2009	Date of Annual General Meeting
20 March 2009	TR-1: Notification of major interests in shares
20 March 2009	TR-1: Notification of major interests in shares
16 March 2009	Final Results for the year ended 31 December 2008
02 March 2009	TR-1: Notification of major interests in shares
27 February 2009	Notice of Announcement of 2008 Final Results
17 February 2009	Chi-Med Announces Completion of Patient Enrolment in its US Phase II Crohn's Disease Clinical Trial of HMPL-004, its Lead Anti-Inflammatory Drug Candidate
22 January 2009	TR-1: Notification of major interests in shares
22 January 2009	TR-1: Notification of major interests in shares
21 January 2009	Holding in Company
19 January 2009	Director's Shareholding
08 January 2009	HMPL-002 Clinical Update
30 December 2008	Blocklisting Six Monthly Return
23 December 2008	Hutchison MediPharma Limited Enters into Drug Discovery and Development Partnership With Ortho-McNeil-Janssen Pharmaceuticals, Inc.
15 December 2008	Director's Shareholding
21 November 2008	Chi-Med Expands Drug Discovery and Development Partnership With Lilly
30 October 2008	Hutchison MediPharma wins the 2008 American College of Gastroenterology International Award
08 October 2008	Board Change
06 August 2008	Interim Results for the Six Months Ended 30 June 2008
06 August 2008	Drug R&D Division New employee share option scheme in Hutchison MediPharma
18 July 2008	Notice of 2008 Interim Results
30 June 2008	Blocklisting Six Monthly Return
10 June 2008	Director's Shareholding
02 June 2008	Board Change
23 May 2008	China Healthcare Division Chi-Med increases ownership of its Hutchison Healthcare joint venture
19 May 2008	Expansion of Consumer Products division Sen launches in 125 Marionnaud beauty stores
09 May 2008	Results of Annual General Meeting
22 April 2008	Holding in Company
09 April 2008	Annual Report 2007 and Notice of Annual General Meeting
31 March 2008	Holding in Company
19 March 2008	Preliminary Results for the year ended 31 December 2007
29 February 2008	Chi-Med Announces Start of Patient Enrolment in a Global Phase IIb Ulcerative Colitis Clinical Trial of HMPL-004, its Leading Anti-Inflammatory Drug Candidate
28 February 2008	Change in the Registered Office Address in the Cayman Islands
28 February 2008	Notice of 2007 Preliminary Results
21 January 2008	Strong growth in China Healthcare division Streamlining of product range set to further improve financial performance
27 December 2007	Block Admission Return
22 November 2007	Chi-Med Plans to Initiate Global Phase IIb Trials of its Lead Anti-Inflammatory Drug Candidate, HMPL-004, in Ulcerative Colitis Patients
20 August 2007	Chi-Med Announces Drug Discovery and Development Agreement with Eli Lilly and Company
09 August 2007	Interim Results for the Six Months Ended 30 June 2007
18 July 2007	Notice of Interim Results
02 July 2007	Chi-Med Announces Positive Phase II Proof-of-Concept Data for HMPL-004 in Ulcerative Colitis
22 June 2007	Block Admission
18 June 2007	Chi-Med locks-in property gain and protects low cost R&D structure through acquisition of Shanghai facility
23 May 2007	Chi-Med completes patient enrolment on its HMPL-004 ulcerative colitis proof-of-concept; Phase II clinical trial in China
22 May 2007	Director's Shareholding
11 May 2007	Results of Annual General Meeting
12 April 2007	Annual Report and Accounts 2006 - Notice of Annual General Meeting
02 April 2007	Board Change
23 March 2007	Director's Shareholding
21 March 2007	Preliminary Results for the year ended 31 December 2006
26 February 2007	Notice of Preliminary Results
17 January 2007	Related party transaction Chi-Med formalises China Sales and Distribution Arrangements
05 January 2007	Appointment of Joint Broker
20 November 2006	Chi-Med and Merck KGaA Start Collaboration to Discover Novel Small Molecule Anti-Cancer Drugs
06 November 2006	Development Agreement with Procter & Gamble for the Discovery and Development of New Active Ingredients for Beauty Products
29 September 2006	Appointment of Senior Independent Director
09 August 2006	Financial Results for the Six Months Ended 30 June 2006
26 July 2006	Notice of Maiden Interim Results
17 July 2006	Trading Update
04 July 2006	Chi-Med plans to broaden clinical trials of its leading oncology drug candidate